Search results for " Lymphocyte Count"

showing 10 items of 62 documents

T helper 1 response is correlated with widespread pain, fatigue, sleeping disorders and the quality of life in patients with fibromyalgia and is modu…

2019

Hyperbaric oxygen therapy (HBOT) has been used as treatment for different clinical conditions, including fibromyalgia (FM). HBOT modulates brain activity, ameliorates chronic pain and modifies the ratio of immune cells. Clinical studies have provided evidence that FM is associated with immune system dysregulation. In the present study we aimed to evaluate the effect of HBOT on immune system and on the quality of life-style of FM patients.Patients with primary FM and controls were treated with HBOT. Physical, emotional and social assessment, quality of sleep, tender points, intensity score, WPI and symptom severity were evaluated before and after HBOT. Furthermore, a characterisation of CD4 …

Hyperbaric OxygenationSettore MED/16 - ReumatologiaFibromyalgiaT1 helper fibromyalgia hyperbaric oxygen therapy immune system pain fatigue sleeping disorders quality of life.Quality of LifeCytokinesHumansTh1 CellsSleepFatigueCD4 Lymphocyte CountClinical and experimental rheumatology
researchProduct

Low Lymphocyte Count and Cardiovascular Diseases

2011

Inflammation plays a crucial pathophysiological role in the entire continuum of the atherosclerotic process, from its initiation, progression, and plaque destabilization leading ultimately to an acute coronary event. Furthermore, once the clinical event has occurred, inflammation also influences the left ventricular remodelling process. Under the same paradigm, there is evidence that lymphocytes play an important role in the modulation of the inflammatory response at every level of the atherosclerotic process. Low lymphocyte count (LLC) is a common finding during the systemic inflammatory response, and clinical and animal studies suggest that LCC plays a putative role in accelerated atheros…

LymphocyteInflammationBiochemistryLymphopeniaDrug DiscoverymedicineAnimalsHumansLymphocyte CountLymphocytesLow lymphocyte countPharmacologybusiness.industryIncidence (epidemiology)Organic ChemistryPrognosismedicine.diseasePathophysiologymedicine.anatomical_structureImmune System DiseasesCardiovascular DiseasesAgeingHeart failureImmunologyMolecular MedicineAnimal studiesmedicine.symptombusinessCurrent Medicinal Chemistry
researchProduct

Serum Malondialdehyde in HIV Seropositive Children

1998

Human immunodeficiency virus (HIV) infection is associated with oxidative stress as it has been demonstrated in adult seropositive individuals. We show in this study that serum malondialdehyde (MDA) concentration of HIV infected children was significantly higher than in control children. Moreover, a statistically significant decreased serum antioxidant status was detected in HIV infected children when compared with controls. No correlation was found in HIV infected children between their clinical or immunological categories, CD4+ lymphocyte count or CD4+/CD8+ ratio, and MDA concentration or serum antioxidant status. Newborn from HIV seropositive mothers had also a higher MDA concentration i…

MaleAdolescentLymphocyteBirth weightCD4-CD8 RatioCD4-CD8 Ratiomedicine.disease_causeBiochemistryAntioxidantschemistry.chemical_compoundMalondialdehydePhysiology (medical)HIV SeropositivitymedicineHumansChildbusiness.industryInfant NewbornInfantGestational ageMalondialdehydePathophysiologyCD4 Lymphocyte CountOxidative Stressmedicine.anatomical_structurechemistryChild PreschoolCord bloodImmunologyFemalebusinessOxidative stressFree Radical Biology and Medicine
researchProduct

Antiretroviral therapy abrogates association between arginase activity and HIV disease severity

2010

AbstractArginase-induced L-arginine deprivation is emerging as a key mechanism for the downregulation of immune responses. We hypothesised that arginase activity increases with disease severity in HIV-seropositive patients. Our results show that peripheral blood mononuclear cells (PBMCs) from 23 HIV-seropositive patients with low CD4+ T cell counts (≤350 cells/μl) expressed significantly more arginase compared with 21 patients with high CD4+ T cell counts. Furthermore, we found a significant association between the two principal prognostic markers used to monitor HIV disease (CD4+ T cell count and plasma viral load) and PBMC arginase activity in antiretroviral therapy naïve patients but not…

MaleAnti-HIV AgentsT cellT cellsCD4 cell countL-arginineHIV InfectionsArgininePeripheral blood mononuclear cellSeverity of Illness Index03 medical and health sciences0302 clinical medicineImmune systemImmunopathologymedicineHumansImmune response030304 developmental biology0303 health sciencesbiologyArginasebusiness.industryPublic Health Environmental and Occupational HealthHIVGeneral MedicineViral Loadbiology.organism_classification3. Good healthCD4 Lymphocyte CountArginaseInfectious Diseasesmedicine.anatomical_structureSociety Meeting PaperLentivirusImmunologyHIV-1Leukocytes MononuclearParasitologyFemaleViral diseasebusinessViral load030217 neurology & neurosurgeryTransactions of the Royal Society of Tropical Medicine and Hygiene
researchProduct

Serum malondialdehyde in HIV-seropositive children negatively correlates with CD4+ lymphocytes count.

1998

Human immunodeficiency virus (HIV) infection is associated with oxidative stress as it has been demonstrated in adult-seropositive individuals. We show in this study that serum malondialdehyde (MDA) concentration of HIV-infected children was significantly higher than in control children. A negative correlation (r = -0.515) was found in HIV-infected children between their CD4+ lymphocyte count, and MDA concentration but not with serum antioxidant status. The increase of MDA concentration in HIV-seropositive children confirms the involvement of oxidative stress in the pathophysiology of this infection also in childhood. Because of the importance of oxidative stress and antioxidants for HIV vi…

MaleAntioxidantHiv seropositivemedicine.medical_treatmentLymphocyteClinical BiochemistryBiologymedicine.disease_causeBiochemistrychemistry.chemical_compoundReference ValuesHIV SeronegativityMalondialdehydeHIV SeropositivitymedicineAdjuvant therapyHumansChildGeneral MedicineMalondialdehydePathophysiologyCD4 Lymphocyte CountOxidative Stressmedicine.anatomical_structurechemistryViral replicationChild PreschoolImmunologyMolecular MedicineRegression AnalysisFemaleOxidative stressBiomarkersBioFactors (Oxford, England)
researchProduct

Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study

2011

Background and objectives: Guidelines indicate a plasma HIV-1 RNA load of 500-1000 copies/mL as the minimal threshold for antiretroviral drug resistance testing. Resistance testing at lower viral load levels may be useful to guide timely treatment switches, although data on the clinical utility of this remain limited. We report here the influence of viral load levels on the probability of detecting drug resistance mutations (DRMs) and other mutations by routine genotypic testing in a large multicentre European cohort, with a focus on tests performed at a viral load <1000 copies/mL. Methods: A total of 16511 HIV-1 reverse transcriptase and protease sequences from 11492 treatment-experienced …

MaleDrug ResistanceHIV InfectionsDrug resistanceCohort Studies0302 clinical medicineGenotypeHIV InfectionPharmacology (medical)030212 general & internal medicineViral0303 health sciencesProteolytic enzymesGenotypic testing; HIV; Viral load; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Europe; Female; Genotype; HIV Infections; HIV-1; Humans; Male; RNA Viral; Viral Proteins; Drug Resistance Viral; Mutation Missense; Viral Load; Pharmacology; Pharmacology (medical); Infectious DiseasesViral LoadGenotypic testing3. Good healthEuropeInfectious DiseasesCohortRNA ViralFemaleViral loadCohort studyHumanMicrobiology (medical)AdultGenotypeAnti-HIV AgentsMutation MissenseBiologySettore MED/17 - MALATTIE INFETTIVE03 medical and health sciencesViral ProteinsSDG 3 - Good Health and Well-beingDrug Resistance ViralHumansViral ProteinPharmacology030306 microbiologyHIVAnti-HIV AgentVirologyReverse transcriptaseCD4 Lymphocyte CountRegimenHIV; genotypic testing; viral loadGenotypic testing; HIV; Viral load; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Resistance Viral; Europe; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Mutation Missense; RNA Viral; Viral Load; Viral ProteinsImmunologyMutationHIV-1RNAMissenseCohort Studie
researchProduct

Patterns of transmitted HIV drug resistance in Europe vary by risk group

2014

BACKGROUND: In Europe, a continuous programme (SPREAD) has been in place for ten years to study transmission of drug resistant HIV. We analysed time trends of transmitted drug resistance mutations (TDRM) in relation to the risk behaviour reported. METHODS: HIV-1 patients newly diagnosed in 27 countries from 2002 through 2007 were included. Inclusion was representative for risk group and geographical distribution in the participating countries in Europe. Trends over time were calculated by logistic regression. RESULTS: From the 4317 patients included, the majority was men-having-sex-with-men -MSM (2084, 48%), followed by heterosexuals (1501, 35%) and injection drug users (IDU) (355, 8%). MSM…

MaleEpidemiologygenotypeHuman immunodeficiency virus 1HIV InfectionsRNA directed DNA polymerase inhibitorhigh risk patientLogistic regressionSettore MED/42 - Igiene Generale E ApplicataMen who have sex with men0302 clinical medicineImmunodeficiency Virusesmiddle agedstatistics and numerical data10. No inequalitySubstance Abuse Intravenous0303 health sciencesadulttransmissionvirus diseasesvirus transmissionhighly active antiretroviral therapyHIV immunopathogenesis3. Good healthMedical MicrobiologyViral Pathogenshigh risk behaviorMedicineScience & Technology - Other TopicsPOPULATIONShealth programanti human immunodeficiency virus agentUSERSmedicine.medical_specialtyScienceSexual BehaviorImmunologySexually Transmitted Diseasesintravenous drug abuse-Microbiology03 medical and health sciencesAntibiotic resistanceSDG 3 - Good Health and Well-beingHuman immunodeficiency virus infectionproteinase inhibitorHumansProtease InhibitorshumanHeterosexualityMicrobial PathogensseroconversionMedicine and health sciencesScience & TechnologyGenitourinary InfectionsMUTATIONSVirologymajor clinical studyLogistic Modelstransmitted drug resistance mutationHeterosexualityHIV-1Viral Diseases:Medical sciences: 700::Basic medical dental and veterinary sciences: 710::Medical immunology: 716 [VDP]drug responsemen who have sex with menDrug resistanceClinical immunologygeographyAPPEARANCEmale homosexualityMedizinische Fakultätimmune system diseasesEpidemiologyINFECTIONMedicine and Health Sciencessubstance abuse030212 general & internal medicineriskMultidisciplinaryACTIVE ANTIRETROVIRAL THERAPYTransmission (medicine)virus mutationQRarticleObstetrics and GynecologyHIV diagnosis and managementMiddle AgedvirologyMultidisciplinary SciencesEuropeInfectious Diseasesfemale:Medisinske fag: 700::Basale medisinske odontologiske og veterinærmedisinske fag: 710::Medisinsk immunologi: 716 [VDP]Reverse Transcriptase InhibitorsHIV clinical manifestationsFemaleepidemiologyblood samplingHIV drug resistanceResearch ArticleAdultRiskrisk-groupAnti-HIV AgentsUrologyprevalenceInfectious Disease Epidemiologysexual behaviorRisk-Takingmaleantiviral resistanceInternal medicineDrug Resistance Viralmedicinecontrolled studyddc:610Homosexuality Male030304 developmental biologydrug resistanceBiology and life sciencesbusiness.industrystatistical modelHIVCD4 lymphocyte countheterosexualitynonnucleoside reverse transcriptase inhibitorHuman immunodeficiency virus 1 infectionDiagnostic medicineINDIVIDUALSdrug effectsWomen's Healthbusinesstrend study
researchProduct

Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy

2021

BACKGROUND: Immediate initiation of antiretroviral therapy (ART) regardless of CD4 cell count reduces risk for AIDS and non-AIDS-related events in asymptomatic, HIV-positive persons and is the standard of care. However, most HIV-positive persons initiate ART when their CD4 count decreases below 500 × 10 9 cells/L. Consequences of delayed ART on risk for non-AIDS-defining and AIDS-defining cancer, one of the most common reasons for death in HIV, are unclear. OBJECTIVE: To estimate the long-term risk difference for cancer with the immediate ART strategy.DESIGN: Multinational prospective cohort study.SETTING: The D:A:D (Data collection on Adverse events of anti-HIV Drugs) study, which included…

MaleHIV AIDSHIV Infections0302 clinical medicineInterquartile rangeRisk FactorsNeoplasmsMedicine030212 general & internal medicineProspective StudiesProspective cohort study0303 health sciencesIncidenceAbsolute risk reductionDrugsGeneral MedicineMiddle AgedViral LoadAntiretroviral therapy3. Good healthAIDSCancer treatmentPrevention policy and public healthCohortInfectious diseasesCohort studiesFemaleViral loadAdultmedicine.medical_specialtyAnti-HIV AgentsHIV Infections/drug therapySocio-culturaleTime-to-Treatment03 medical and health sciencesAcquired immunodeficiency syndrome (AIDS)SDG 3 - Good Health and Well-beingInternal medicineInternal MedicineHumansAdverse effect030306 microbiologybusiness.industryHIVCancermedicine.diseaseCD4 Lymphocyte CountCancer.Anti-HIV Agents/therapeutic use[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessNeoplasms/epidemiologyAnnals of Internal Medicine
researchProduct

No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy

2011

An investigation was undertaken to determine whether specific pol mutations hinder long-term immune recovery regardless of virological response. In total, 826 patients with >50 HIV RNA copies/ml, who underwent genotypic resistance testing between 1 January 2000 and 31 December 2003 after >3 years of antiretroviral treatment, and were followed up for >3 years after genotypic resistance testing, were analyzed retrospectively. The outcome of the study was the lack of immune recovery after >3 years of follow-up, defined as a slope by linear regression 50 copies/ml divided by the number of HIV RNA measurements during follow-up. Logistic regression was used for univariable and multivariable analy…

MaleHIV InfectionsDrug resistanceLogistic regressionResistance to nucleoside reverse transcriptase inhibitorCD4+ T-lymphocyteRetrospective StudieImmunopathologyAntiretroviral Therapy Highly ActiveResistance to non-nucleoside reverse transcriptase inhibitorgeneticsResistance to protease inhibitorHIV Infectionresistance to nucleoside reverse transcriptase inhibitorsViralSidaresistance to protease inhibitorsbiologyReverse-transcriptase inhibitorViral LoadGenes poldrug therapy/immunology/virologyReverse Transcriptase InhibitorInfectious DiseasesTreatment Outcomeresistance to non-nucleoside reverse transcriptase inhibitorsReverse Transcriptase InhibitorsFemaleViral loadmedicine.drugHumanpolAnti-HIV AgentsAntiretroviral TherapyViremiaInfectious DiseaseSettore MED/17 - MALATTIE INFETTIVEpharmacology/therapeutic useAcquired immunodeficiency syndrome (AIDS)VirologyDrug Resistance ViralmedicineHumansHighly ActiveRetrospective StudiesAnti-HIV Agents; pharmacology/therapeutic use Antiretroviral Therapy; Highly Active CD4 Lymphocyte Count Drug Resistance; Viral; genetics Female Genes; pol HIV Infections; drug therapy/immunology/virology HIV-1; drug effects/enzymology/genetics Humans Male Mutation Retrospective Studies Reverse Transcriptase Inhibitors; therapeutic use Treatment Outcome Viral Loaddrug resistanceAnti-HIV Agentbiology.organism_classificationmedicine.diseaseVirologyCD4 Lymphocyte CountGenesdrug effects/enzymology/geneticstherapeutic useMutationCD4+ T-lymphocytesHIV-1
researchProduct

Therapeutic implications of low lymphocyte count in non-ST segment elevation acute coronary syndromes

2009

Abstract Background Low lymphocyte count (LLC), a surrogate for inflammation, has emerged as a potential risk factor for cardiovascular outcomes, especially new ischemic events. To identify patients with non-ST segment elevation acute coronary syndromes (NSTEACS) who benefit from an invasive revascularization strategy remains a challenge. We sought to determine if patients with high-risk NSTEACS who exhibited LLC have a greater reduction in long-term post-discharge myocardial infarction (MI) when managed under a revascularization invasive strategy (RIS) as compared with conservative strategy (CS). Methods Nine hundred seventy two consecutive patients with high-risk NSTEACS were treated unde…

MaleInvasive strategymedicine.medical_specialtyLymphocytemedicine.medical_treatmentMyocardial InfarctionRevascularizationElectrocardiographyRisk FactorsLymphopeniaInternal medicineMyocardial RevascularizationInternal MedicineHumansMedicineST segmentLymphocyte CountMyocardial infarctionAcute Coronary SyndromeLow lymphocyte countAgedProportional Hazards ModelsRetrospective Studiesbusiness.industryProportional hazards modelPrognosismedicine.diseaseTreatment Outcomemedicine.anatomical_structureQuartileCardiologyFemalebusinessEuropean Journal of Internal Medicine
researchProduct